Synartro granted European patent

Report this content

Synartro’s patent application for its drug delivery platform has been granted by the European Patent Office. The patent strengthens the position of the company’s lead candidate SYN321, which is developed for treatment of knee osteoarthritis. The granted patent also protects further development within other areas and indications based on the platform.

The patent (European Patent No. 3226905) covers the company’s mechanism for linking hyaluronan with another active substance, as well as the method to produce the linking mechanism. With the patent, Synartro is given exclusivity in Europe until 2035, with the possibility of a five year extension. Synartro was previously granted a patent for SYN321 in the United States.   

Synartro has also received a notice of allowance regarding SYN321 from the Canadian Intellectual Property Office. A granted patent for Canada is expected during the second quarter of 2022.  

”With a European patent for SYN321 our position globally is strengthened. We are continuously working to develop our platform and with patents covering North America and Europe we have a strong foundation to build on,” says Mia Brundin, CEO at Synartro.  

SYN321 is a local injection treatment combining diclofenac and hyaluronan through Synartro’s patented technology. The aim is to provide patients with sustained pain relief without systemic side-effects.

North America and Europe are the largest markets for osteoarthritis treatments and the primary focus of Synartro. Global sales of osteoarthritis treatments amounted to USD 7.3 billion in 2020.


Mia Brundin, CEO 
Phone: +46 73 433 60 25

About Synartro

Synartro is a Swedish pharmaceutical company developing local injection treatments that provide superior and sustained efficacy with minimal systemic side-effects. This is achieved by adding existing drugs to our patented delivery platform.

Our pre-clinical lead program focuses on a novel therapy using our compound SYN321 for the treatment of osteoarthritis (OA). Currently this disease leaves up to 50% of patients without adequate pain relief.

In addition to the founders, major shareholders include life science investment company Linc AB.